Results 31 to 40 of about 65,110 (152)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2016
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj   +1 more source

Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?

Advances in Perioperative Care
In recent years, concerns have arisen regarding the perioperative use of glucagon-like peptide-1 receptor agonist medications and a possible association with increased risk of pulmonary aspiration. The evidence in this setting remains limited.
Louisa Frances Lowes
doaj   +2 more sources

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice

Journal of Cardiovascular Development and Disease, 2023
Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou, Zhaoshun Yuan, Min Wang, Zhiyuan Zhang, Changming Tan, Jiaolian Yu, Yanfeng Bi, Xiaobo Liao, Xinmin Zhou, Md Sayed Ali Sheikh, Dafeng Yang   +10 more
doaj   +1 more source

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

Neural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun, Liqin Huang, Gege Jiang, Guanfeng Xie, Xiaoyi Li, Xiufeng Wang, Hongxiu Guo, Cailin Wang, Siyi Zheng, Gang Li, Jing Xiong   +10 more
doaj   +1 more source

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Сахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova   +2 more
doaj   +1 more source

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]

Endocrinology and Metabolism, 2014
BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon, Min Jung Bae, Ju In Kim, Joo Hyoung Kim, Soo Jong Choi, Su Kyoung Kwon, Joon Hyop An, Sang Soo Kim, Bo Hyun Kim, Yong Ki Kim, In Joo Kim   +10 more
doaj   +1 more source

Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs

Scientific Reports
Insulin secretion is impaired in individuals with cystic fibrosis (CF), contributing to high rates of CF-related diabetes (CFRD) and substantially increasing disease burden. To develop improved therapies for CFRD, better knowledge of pancreatic pathology
Sina A. Gharib, Rachna Vemireddy, Joseph J. Castillo, Brendy S. Fountaine, Theo K. Bammler, James W. MacDonald, Rebecca L. Hull-Meichle, Sakeneh Zraika   +7 more
doaj   +1 more source

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Diabetes, Metabolic Syndrome and Obesity, 2019
Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-
Howell R, Wright AM, Clements JN
doaj  

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot

Biomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero, David Rodríguez de Vera Gómez, Pablo Rodríguez de Vera Gómez, Luis María Gordillo Fernández   +3 more
doaj   +1 more source

Glucagon like‐peptide 1 receptor and the liver [PDF]

Liver International, 2011
Pedersen, Jens, Holst, Jens Juul
openaire   +3 more sources